United States· US:0409-0801_5db62458-cb13-4a2a-b7ee-6ed3fca88a8c
Nipent
A pentostatin product containing pentostatin, registered in United States by Hospira, Inc.. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Pentostatin is registered in 5 of 19 countries.
Countries holding a registration under ATC L01XX08 (pentostatin), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Pentostatin · ATC L01XX08
5 / 19 countries
- Franceprice
- Germany
- Ireland
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PENTOSTATIN
- Manufacturer
- Hospira, Inc.
- Country
- United States (US)
- ATC code
- L01XX08
- ATC class
- Pentostatin
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc110409-0801-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
130 interactions on record for pentostatin.
Graded by severity as the source publishes them — 31 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Pentostatin · interactions on record
130 records
- 31 severe
- 83 moderate
- 16 minor
Most severe, free to view
- CladribineL01BB04severe
- FludarabineL01BB05severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Pentostatin in 5 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- GermanyNipentPfizer Pharma Gmbh
- SpainNIPENT 10 mg POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSIONPfizer S.L.
- FranceNIPENT 10 mg, poudre pour solution pour injection, poudre pour solution pour perfusionPFIZER HOLDING FRANCE
- United KingdomNipent 10mg powder for solution for injection vialsPfizer Ltd
- IrelandNIPENT 10 mg powder for solution for injection, powder for solution for infusionPfizer Healthcare Ireland Unlimited Company
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Germany · Nipent
- Spain · Nipent
- France · Nipent
- United Kingdom (Northern Ireland) · Nipent
- Greece · Nipent
- Ireland · Nipent
- Italy · Nipent
- Malta · Nipent
- Portugal · Nipent
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6bbf168f-3186-4ffb-8e9d-b551a3b03476 GET /v1/drugs/6bbf168f-3186-4ffb-8e9d-b551a3b03476?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "2",
"substance": "PENTOSTATIN",
"productndc": "0409-0801",
"dosage_form": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "NDA020122",
"marketing_category": "NDA"
}See everything about pentostatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.